240 related articles for article (PubMed ID: 29914847)
41. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery.
Jalava K; Eko FO; Riedmann E; Lubitz W
Expert Rev Vaccines; 2003 Feb; 2(1):45-51. PubMed ID: 12901596
[TBL] [Abstract][Full Text] [Related]
42. Macrophage-
Escobar A; Rodas PI; Acuña-Castillo C
Front Immunol; 2018; 9():3044. PubMed ID: 30627130
[No Abstract] [Full Text] [Related]
43. Analysis of immune responses in genital tracts of mice immunised with purified ribosomal fractions of Neisseria gonorrhoeae.
Kita E; Kashiba S
Br J Vener Dis; 1984 Aug; 60(4):219-25. PubMed ID: 6430462
[TBL] [Abstract][Full Text] [Related]
44. Biology of the Gonococcus: Disease and Pathogenesis.
Shaughnessy J; Ram S; Rice PA
Methods Mol Biol; 2019; 1997():1-27. PubMed ID: 31119614
[TBL] [Abstract][Full Text] [Related]
45. Characterization and specificity of antibodies to protein I of Neisseria gonorrhoeae produced by injection with various protein I-adjuvant preparations.
Wetzler LM; Blake MS; Gotschlich EC
J Exp Med; 1988 Nov; 168(5):1883-97. PubMed ID: 3141555
[TBL] [Abstract][Full Text] [Related]
46. Phage proteins are expressed on the surface of Neisseria gonorrhoeae and are potential vaccine candidates.
Kłyż A; Piekarowicz A
PLoS One; 2018; 13(8):e0202437. PubMed ID: 30138416
[TBL] [Abstract][Full Text] [Related]
47. Pasteurella multocida inactivated with ferric chloride and adjuvanted with bacterial DNA is a potent and efficacious vaccine in Balb/c mice.
Homayoon M; Tahamtan Y; Kargar M; Hosseini SMH; Akhavan Sepahy A
J Med Microbiol; 2018 Sep; 67(9):1383-1390. PubMed ID: 30016232
[TBL] [Abstract][Full Text] [Related]
48. Assessment of the immune responses to Treponema pallidum Gpd DNA vaccine adjuvanted with IL-2 and chitosan nanoparticles before and after Treponema pallidum challenge in rabbits.
Zhao F; Zhang X; Liu S; Zeng T; Yu J; Gu W; Zhang Y; Chen X; Wu Y
Sci China Life Sci; 2013 Feb; 56(2):174-80. PubMed ID: 23334700
[TBL] [Abstract][Full Text] [Related]
49. Problems posed by potential gonococcal vaccines viewed from the vantage point of a control agency.
Robbins JB
Br J Vener Dis; 1977 Jun; 53(3):170-2. PubMed ID: 406011
[TBL] [Abstract][Full Text] [Related]
50. Human Immune Responses and the Natural History of
Lovett A; Duncan JA
Front Immunol; 2018; 9():3187. PubMed ID: 30838004
[TBL] [Abstract][Full Text] [Related]
51. Common heat stable protective antigen in gonococci.
Ito JI; Corbeil LB; Wunderlich AC; McCutchan JA; Braude AI
Trans Assoc Am Physicians; 1979; 92():160-8. PubMed ID: 95067
[TBL] [Abstract][Full Text] [Related]
52. The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.
Rubin DHF; Ross JDC; Grad YH
Transl Res; 2020 Jun; 220():122-137. PubMed ID: 32119845
[TBL] [Abstract][Full Text] [Related]
53. Novel Whole-Cell Inactivated
Gala RP; Zaman RU; D'Souza MJ; Zughaier SM
Vaccines (Basel); 2018 Sep; 6(3):. PubMed ID: 30181504
[No Abstract] [Full Text] [Related]
54. Vaccines against gonorrhea: current status and future challenges.
Jerse AE; Bash MC; Russell MW
Vaccine; 2014 Mar; 32(14):1579-87. PubMed ID: 24016806
[TBL] [Abstract][Full Text] [Related]
55. Absence of bactericidal antibodies against Group-I lipopolysaccharide determinants of Neisseria gonorrhoeae during human infection.
Blackwell CC; Winstanley FP; Weir DM; Kinane DF
J Med Microbiol; 1984 Jun; 17(3):353-6. PubMed ID: 6427466
[TBL] [Abstract][Full Text] [Related]
56. Antibodies with higher bactericidal activity induced by a Neisseria gonorrhoeae Rmp deletion mutant strain.
Li G; Xie R; Zhu X; Mao Y; Liu S; Jiao H; Yan H; Xiong K; Ji M
PLoS One; 2014; 9(3):e90525. PubMed ID: 24594737
[TBL] [Abstract][Full Text] [Related]
57. Assessment of Serum Bactericidal and Opsonophagocytic Activity of Antibodies to Gonococcal Vaccine Targets.
Semchenko EA; Jen FE; Jennings MP; Seib KL
Methods Mol Biol; 2022; 2414():363-372. PubMed ID: 34784046
[TBL] [Abstract][Full Text] [Related]
58. Natural serum bactericidal activity against Neisseria gonorrhoeae isolates from disseminated, locally invasive, and uncomplicated disease.
Rice PA; McCormack WM; Kasper DL
J Immunol; 1980 May; 124(5):2105-9. PubMed ID: 6767783
[No Abstract] [Full Text] [Related]
59. [Pyrogenal-vaccine therapy of men with gonorrhea].
Shamshin NF; Malykh VA
Vestn Dermatol Venerol; 1980 Nov; (11):62-4. PubMed ID: 6778014
[No Abstract] [Full Text] [Related]
60. Mucosal Neisseria gonorrhoeae coinfection during HIV acquisition is associated with enhanced systemic HIV-specific CD8 T-cell responses.
Sheung A; Rebbapragada A; Shin LY; Dobson-Belaire W; Kimani J; Ngugi E; MacDonald KS; Bwayo JJ; Moses S; Gray-Owen S; Kaul R;
AIDS; 2008 Sep; 22(14):1729-37. PubMed ID: 18753933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
